Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Arnold Vulto

Researcher

Erasmus University Rotterdam

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Articles (14)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Niek van Til

Assistant professor

Amsterdam UMC Locatie VUmc

NETHERLANDS

View details

Patrick Verschueren

Full Professor

Katholieke Universiteit Leuven

BELGIUM

View details

Stephanie Leigh

Director - WITS Pharmacy Regulatory Sciences Hub (PRSH)

University of Witwatersrand

SOUTH AFRICA

View details

Denis Mulleman

Professor

Université de Tours

FRANCE

View details

Katerina Chatzidionysiou

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Arnold Vulto

Research Interests

Explore related searches

Articles (14)

A university-certified course on dossier assessment for regulatory scientists in Africa—Reporting on our 5-year experience

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe

Barriers to adoption of biosimilar insulins in Europe: A mixed‐methods study

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study

Evolving global regulatory landscape for approval of biosimilars

Drawing on collective action theory to foster sustainable biosimilar markets–insights from co-creation workshops with UK and Belgian stakeholders

Mitigating the Nocebo Effect in Biosimilar Use and Switching

Leveraging the holistic benefits of biosimilars in Europe - part 2

Capturing the holistic value of biosimilars in Europe–part 1: a historical perspective

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study

Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends

The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis

Collaborators (5)

Niek van Til

Patrick Verschueren

Stephanie Leigh

Denis Mulleman

Katerina Chatzidionysiou

Make your next move.